{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:25:49Z","timestamp":1784903149778,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Breast Cancer Trials Australia and New Zealand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41416-018-0349-6","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T06:02:56Z","timestamp":1547704976000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer"],"prefix":"10.1038","volume":"120","author":[{"given":"Chee Khoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lieschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath","family":"Badger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Macnab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond Michael","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"349_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245\u2013251 (2010).","journal-title":"Lancet"},{"key":"349_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).","journal-title":"J. Clin. Oncol."},{"key":"349_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852\u2013861 (2011).","journal-title":"Lancet Oncol."},{"key":"349_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"New Engl. J. Med."},{"key":"349_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"New Engl. J. Med."},{"key":"349_CR6","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512\u20132519 (2010).","journal-title":"J. Clin. Oncol."},{"key":"349_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"SB Kaye","year":"2012","unstructured":"Kaye, S. B. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a Poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372\u2013379 (2012).","journal-title":"J. Clin. Oncol."},{"key":"349_CR8","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1158\/1078-0432.CCR-07-4953","volume":"14","author":"B Evers","year":"2008","unstructured":"Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916\u20133925 (2008).","journal-title":"Clin. Cancer Res."},{"key":"349_CR9","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079\u201317084 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"349_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza, A. M. et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16, 87\u201397 (2015).","journal-title":"Lancet Oncol."},{"key":"349_CR11","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","volume":"25","author":"J Balma\u00f1a","year":"2014","unstructured":"Balma\u00f1a, J. et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann. Oncol. 25, 1656\u20131663 (2014).","journal-title":"Ann. Oncol."},{"key":"349_CR12","first-page":"dju089","volume":"106","author":"JM Lee","year":"2014","unstructured":"Lee, J.-M. et al. Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J. Natl Cancer Inst. 106, dju089 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"349_CR13","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1186\/bcr3484","volume":"15","author":"RA Dent","year":"2013","unstructured":"Dent, R. A. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 15, R88\u2013R88 (2013).","journal-title":"Breast Cancer Res."},{"key":"349_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/annonc\/mdj066","volume":"17","author":"M Colleoni","year":"2006","unstructured":"Colleoni, M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17, 232\u2013238 (2006).","journal-title":"Ann. Oncol."},{"key":"349_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73\u201380 (2002).","journal-title":"Ann. Oncol."},{"key":"349_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia, A. A. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J. Clin. Oncol. 26, 76\u201382 (2008).","journal-title":"J. Clin. Oncol."},{"key":"349_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/pbc.24697","volume":"61","author":"RE Norris","year":"2014","unstructured":"Norris, R. E., Adamson, P. C., Nguyen, V. T. & Fox, E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr. Blood. Cancer 61, 145\u2013150 (2014).","journal-title":"Pediatr. Blood. Cancer"},{"key":"349_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins, T. A. et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol. Cancer Res. 13, 1465\u20131477 (2015).","journal-title":"Mol. Cancer Res."},{"key":"349_CR19","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"issue":"7","key":"349_CR20","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","volume":"21","author":"S. Kummar","year":"2015","unstructured":"Kummar, S. et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin. Cancer Res. 21, 1574\u20131582 (2015).","journal-title":"Clinical Cancer Research"},{"issue":"18","key":"349_CR21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","volume":"92","author":"I. Vergote","year":"2000","unstructured":"Vergote, I. et al. Re: New guidelines to evaluate the response to treatment in solid tumors [Ovarian Cancer]. J. Natl. Cancer Institute 92, 1534\u20131535 (2000).","journal-title":"Journal of the National Cancer Institute"},{"key":"349_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/chromatography1020082","volume":"1","author":"J Roth","year":"2014","unstructured":"Roth, J. et al. A sensitive and robust ultra HPLC assay with tandem mass spectrometric detection for the quantitation of the PARP inhibitor olaparib (AZD2281) in human plasma for pharmacokinetic application. Chromatography 1, 82 (2014).","journal-title":"Chromatography"},{"key":"349_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","volume":"11","author":"J Mateo","year":"2016","unstructured":"Mateo, J. et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target. Oncol. 11, 401\u2013415 (2016).","journal-title":"Target. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0349-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:55Z","timestamp":1684616635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0349-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"28 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}